ProKidney Future Growth
Future criteria checks 0/6
ProKidney is forecast to grow earnings and revenue by 1% and 64.3% per annum respectively. EPS is expected to grow by 4.2% per annum. Return on equity is forecast to be -47.1% in 3 years.
Key information
1.0%
Earnings growth rate
4.2%
EPS growth rate
| Biotechs earnings growth | 29.6% |
| Revenue growth rate | 64.3% |
| Future return on equity | -47.1% |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Jan 31We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
Nov 18
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
Aug 12We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth
May 12Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
Nov 17ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business
Mar 14ProKidney reports Q2 2022 results
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 105 | -115 | -235 | -228 | 2 |
| 12/31/2026 | N/A | -107 | -216 | -160 | 3 |
| 12/31/2025 | N/A | -73 | -177 | -150 | 3 |
| 12/31/2024 | N/A | -58 | -127 | -102 | 3 |
| 9/30/2024 | N/A | -46 | -133 | -128 | N/A |
| 6/30/2024 | N/A | -39 | -153 | -122 | N/A |
| 3/31/2024 | N/A | -35 | -133 | -99 | N/A |
| 12/31/2023 | N/A | -35 | -124 | -90 | N/A |
| 9/30/2023 | N/A | -36 | -113 | -80 | N/A |
| 6/30/2023 | N/A | -33 | -85 | -80 | N/A |
| 3/31/2023 | N/A | 43 | -90 | -88 | N/A |
| 12/31/2022 | N/A | -14 | -79 | -77 | N/A |
| 9/30/2022 | N/A | -22 | -76 | -74 | N/A |
| 6/30/2022 | N/A | -31 | -73 | -70 | N/A |
| 3/31/2022 | N/A | -111 | -63 | -59 | N/A |
| 12/31/2021 | N/A | -55 | -55 | -50 | N/A |
| 9/30/2021 | N/A | -49 | -52 | -45 | N/A |
| 12/31/2020 | N/A | -27 | -31 | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PROK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PROK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PROK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PROK is forecast to have no revenue next year.
High Growth Revenue: PROK is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PROK is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 16:04 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProKidney Corp. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Vamil Divan | Guggenheim Securities, LLC |